相关实验视频

Updated: Jun 26, 2026

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

通过IL-2介导的肝毒性:基于irAOP概念的知识差距识别

Luise A Roser¹, Christina Sakellariou², Malin Lindstedt²

¹Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Frankfurt am Main, Germany.

Journal of immunotoxicology

|April 5, 2024

概括

药物诱导的肝损伤是一个关键的安全问题. 使用IL-2作为模型的免疫相关不良结果途径 (irAOP) 方法提供了一种预测和理解这些药物副作用的新方法.

科学领域:

毒理学毒理学毒理学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

药物诱导的肝毒性是药物开发中的一个重大挑战,往往是临床前模型预测的很差.
将免疫系统反应纳入安全性评估对于识别潜在的药物诱导肝损伤至关重要.
目前的临床前模型往往无法准确预测药物对人类肝脏的损伤.

研究的目的:

开发和验证一种与免疫相关的不良结果途径 (irAOP) 模型,用于药物诱导的肝毒性.
通过使用免疫安全阿凡达 (imSAVAR) 框架建立免疫媒介性肝损伤的预测工具.
剖析药物诱导的肝损伤背后的分子机制,并确定关键的贡献因素.

主要方法:

基于肝毒性的irAOP模型的开发.
利用复合人体IL-2 (阿尔德斯莱金) 作为一个案例研究,由于广泛的可用数据.
使用与IL-2治疗相关的临床数据验证了irAOP的可预测性.

主要成果:

为IL-2诱导的肝毒性产生了一个全面的假定irAOP.
模型irAOP证明了用临床数据验证可预测性的潜力.
虽然IL-2治疗在癌症治疗中有效,但已知会导致肝损伤,为该模型提供了坚实的基础.

结论:

以IL-2肝毒性模型为例的irAOP方法为评估药物诱导的肝损伤提供了一个新的框架.
这种方法对于改善药品,特别是免疫疗法的临床前安全性评估至关重要.
开发的irAOP指南将推动免疫媒介肝毒性研究,并加强药物安全性评估.

关键词:

负面结果的途径.不良事件是不良事件.药物诱导的肝损伤是药物诱导的肝毒性肝毒性肝毒性免疫安全免疫安全免疫疗法免疫疗法介质蛋白-2 介质蛋白-2 介质蛋白-2 临床前模型的临床前模型

更多相关视频

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube

Published on: April 28, 2020

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

Cirrhosis II: Pathophysiology

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...